600222，控制权或生变，明起停牌

Group 1 - The controlling shareholder of Tailong Pharmaceutical is planning to transfer shares, which may lead to a change in company control. The company's stock will be suspended from trading starting December 2 [1][3][6] - The suspension of trading is expected to last no more than two trading days, during which the company will comply with information disclosure obligations as per legal regulations [3][6] - As of the end of the third quarter, the controlling shareholder, Zhengzhou TaiRong Industrial Investment Co., holds 82,441,168 shares, accounting for 14.37% of the total shares [8][9] Group 2 - For the first three quarters of the year, Tailong Pharmaceutical reported a revenue of 1.187 billion yuan, a year-on-year decrease of 11.47%, and a net profit attributable to shareholders of 25.33 million yuan, down 12.36% year-on-year [11][12] - The company's main business includes drug manufacturing and research services, covering four segments: drug formulation, traditional Chinese medicine pieces, drug research services, and drug material circulation [8]